Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 1
2017 3
2018 3
2019 4
2020 1
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
PDGFRβ promotes oncogenic progression via STAT3/STAT5 hyperactivation in anaplastic large cell lymphoma.
Garces de Los Fayos Alonso I, Zujo L, Wiest I, Kodajova P, Timelthaler G, Edtmayer S, Zrimšek M, Kollmann S, Giordano C, Kothmayer M, Neubauer HA, Dey S, Schlederer M, Schmalzbauer BS, Limberger T, Probst C, Pusch O, Högler S, Tangermann S, Merkel O, Schiefer AI, Kornauth C, Prutsch N, Zimmerman M, Abraham B, Anagnostopoulos J, Quintanilla-Martinez L, Mathas S, Wolf P, Stoiber D, Staber PB, Egger G, Klapper W, Woessmann W, Look TA, Gunning P, Turner SD, Moriggl R, Lagger S, Kenner L. Garces de Los Fayos Alonso I, et al. Mol Cancer. 2022 Aug 31;21(1):172. doi: 10.1186/s12943-022-01640-7. Mol Cancer. 2022. PMID: 36045346 Free PMC article.
The Bone's Role in Myeloid Neoplasia.
Kazianka L, Staber PB. Kazianka L, et al. Int J Mol Sci. 2020 Jul 1;21(13):4712. doi: 10.3390/ijms21134712. Int J Mol Sci. 2020. PMID: 32630305 Free PMC article. Review.
Combined chemosensitivity and chromatin profiling prioritizes drug combinations in CLL.
Schmidl C, Vladimer GI, Rendeiro AF, Schnabl S, Krausgruber T, Taubert C, Krall N, Pemovska T, Araghi M, Snijder B, Hubmann R, Ringler A, Runggatscher K, Demirtas D, de la Fuente OL, Hilgarth M, Skrabs C, Porpaczy E, Gruber M, Hoermann G, Kubicek S, Staber PB, Shehata M, Superti-Furga G, Jäger U, Bock C. Schmidl C, et al. Nat Chem Biol. 2019 Mar;15(3):232-240. doi: 10.1038/s41589-018-0205-2. Epub 2019 Jan 28. Nat Chem Biol. 2019. PMID: 30692684 Free PMC article.
Dependency on the TYK2/STAT1/MCL1 axis in anaplastic large cell lymphoma.
Prutsch N, Gurnhofer E, Suske T, Liang HC, Schlederer M, Roos S, Wu LC, Simonitsch-Klupp I, Alvarez-Hernandez A, Kornauth C, Leone DA, Svinka J, Eferl R, Limberger T, Aufinger A, Shirsath N, Wolf P, Hielscher T, Sternberg C, Aberger F, Schmoellerl J, Stoiber D, Strobl B, Jäger U, Staber PB, Grebien F, Moriggl R, Müller M, Inghirami GG, Sanda T, Look AT, Turner SD, Kenner L, Merkel O. Prutsch N, et al. Leukemia. 2019 Mar;33(3):696-709. doi: 10.1038/s41375-018-0239-1. Epub 2018 Aug 21. Leukemia. 2019. PMID: 30131584 Free PMC article.
CD44 is a RAS/STAT5-regulated invasion receptor that triggers disease expansion in advanced mastocytosis.
Mueller N, Wicklein D, Eisenwort G, Jawhar M, Berger D, Stefanzl G, Greiner G, Boehm A, Kornauth C, Muellauer L, Sehner S, Hoermann G, Sperr WR, Staber PB, Jaeger U, Zuber J, Arock M, Schumacher U, Reiter A, Valent P. Mueller N, et al. Blood. 2018 Nov 1;132(18):1936-1950. doi: 10.1182/blood-2018-02-833582. Epub 2018 Jul 17. Blood. 2018. PMID: 30018080 Free PMC article.
Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy.
Porpaczy E, Tripolt S, Hoelbl-Kovacic A, Gisslinger B, Bago-Horvath Z, Casanova-Hevia E, Clappier E, Decker T, Fajmann S, Fux DA, Greiner G, Gueltekin S, Heller G, Herkner H, Hoermann G, Kiladjian JJ, Kolbe T, Kornauth C, Krauth MT, Kralovics R, Muellauer L, Mueller M, Prchal-Murphy M, Putz EM, Raffoux E, Schiefer AI, Schmetterer K, Schneckenleithner C, Simonitsch-Klupp I, Skrabs C, Sperr WR, Staber PB, Strobl B, Valent P, Jaeger U, Gisslinger H, Sexl V. Porpaczy E, et al. Blood. 2018 Aug 16;132(7):694-706. doi: 10.1182/blood-2017-10-810739. Epub 2018 Jun 14. Blood. 2018. PMID: 29907599 Free PMC article.
Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study.
Snijder B, Vladimer GI, Krall N, Miura K, Schmolke AS, Kornauth C, Lopez de la Fuente O, Choi HS, van der Kouwe E, Gültekin S, Kazianka L, Bigenzahn JW, Hoermann G, Prutsch N, Merkel O, Ringler A, Sabler M, Jeryczynski G, Mayerhoefer ME, Simonitsch-Klupp I, Ocko K, Felberbauer F, Müllauer L, Prager GW, Korkmaz B, Kenner L, Sperr WR, Kralovics R, Gisslinger H, Valent P, Kubicek S, Jäger U, Staber PB, Superti-Furga G. Snijder B, et al. Lancet Haematol. 2017 Dec;4(12):e595-e606. doi: 10.1016/S2352-3026(17)30208-9. Epub 2017 Nov 15. Lancet Haematol. 2017. PMID: 29153976 Free PMC article. Clinical Trial.
First-in-human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemia.
Boidol B, Kornauth C, van der Kouwe E, Prutsch N, Kazianka L, Gültekin S, Hoermann G, Mayerhoefer ME, Hopfinger G, Hauswirth A, Panny M, Aretin MB, Hilgarth B, Sperr WR, Valent P, Simonitsch-Klupp I, Moriggl R, Merkel O, Kenner L, Jäger U, Kubicek S, Staber PB. Boidol B, et al. Blood. 2017 Dec 7;130(23):2499-2503. doi: 10.1182/blood-2017-05-785683. Epub 2017 Sep 27. Blood. 2017. PMID: 28972014 Free article.
12 results